secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001628280-26-001955
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences reports ~$137M cash, outlines 2026 clinical milestones for HBV and DMD programs
--------------------------------------------------------------------------------

- Preliminary cash ~$137M as of Dec 31, 2025; cash runway expected through 2028.
- PBGENE-HBV: Phase 1/2a ELIMINATE-B dosing Cohorts 3-5 ongoing; additional biopsy data expected H1 2026.
- PBGENE-DMD: IND clearance expected Q1 2026; first patient dosing late-Q1/early-Q2 2026; initial data by year-end 2026.
- Partnered programs: iECURE ECUR-506 RMAT designation; Imugene milestone $8M received; TG Therapeutics potential $7.5M milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026001955/0001628280-26-001955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026001955/dtil-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer